<?xml version="1.0" encoding="UTF-8"?>
<results title="funder">
 <result pre="at concentrations of 0.5, 5, 50, and 500Â Ã— 10âˆ’6" exact="m" post="while all the remaining drugs were tested at concentrations"/>
 <result pre="at concentrations of 0.1, 1, 10, and 100Â Ã— 10âˆ’6" exact="m" post="(Table S1, Supporting Information). As monotherapies, none of the"/>
 <result pre="and concurrent treatment with Nonoptimal Combo 1 (0.5Â Ã— 10âˆ’6" exact="m" post="Azithromycin, 5Â Ã— 10âˆ’6 m Chloroquine Diphosphate, 0.5Â Ã—"/>
 <result pre="Combo 1 (0.5Â Ã— 10âˆ’6 m Azithromycin, 5Â Ã— 10âˆ’6" exact="m" post="Chloroquine Diphosphate, 0.5Â Ã— 10âˆ’6 m Omeprazole Sodium and"/>
 <result pre="Azithromycin, 5Â Ã— 10âˆ’6 m Chloroquine Diphosphate, 0.5Â Ã— 10âˆ’6" exact="m" post="Omeprazole Sodium and 25Â Ã— 10âˆ’6 m Ribavirin). â€œNonâ€�opt."/>
 <result pre="0.5Â Ã— 10âˆ’6 m Omeprazole Sodium and 25Â Ã— 10âˆ’6" exact="m" post="Ribavirin). â€œNonâ€�opt. Combo #2â€� indicates the host cells with"/>
 <result pre="and concurrent treatment with Nonoptimal Combo 2 (0.5Â Ã— 10âˆ’6" exact="m" post="Azithromycin, 0.5Â Ã— 10âˆ’6 m Chloroquine Diphosphate, 5Â Ã—"/>
 <result pre="Combo 2 (0.5Â Ã— 10âˆ’6 m Azithromycin, 0.5Â Ã— 10âˆ’6" exact="m" post="Chloroquine Diphosphate, 5Â Ã— 10âˆ’6 m Omeprazole Sodium and"/>
 <result pre="Azithromycin, 0.5Â Ã— 10âˆ’6 m Chloroquine Diphosphate, 5Â Ã— 10âˆ’6" exact="m" post="Omeprazole Sodium and 25Â Ã— 10âˆ’6 m Ribavirin). â€œOptimal"/>
 <result pre="5Â Ã— 10âˆ’6 m Omeprazole Sodium and 25Â Ã— 10âˆ’6" exact="m" post="Ribavirin). â€œOptimal Combo #1â€� indicates the host cells with"/>
 <result pre="and concurrent treatment with Optimal Combo 1 (5Â Ã— 10âˆ’6" exact="m" post="Amantadine HCl, 5Â Ã— 10âˆ’6 m Azithromycin, 0.5Â Ã—"/>
 <result pre="1 (5Â Ã— 10âˆ’6 m Amantadine HCl, 5Â Ã— 10âˆ’6" exact="m" post="Azithromycin, 0.5Â Ã— 10âˆ’6 m Chloroquine Diphosphate and 25Â"/>
 <result pre="Amantadine HCl, 5Â Ã— 10âˆ’6 m Azithromycin, 0.5Â Ã— 10âˆ’6" exact="m" post="Chloroquine Diphosphate and 25Â Ã— 10âˆ’6 m Ribavirin). â€œOptimal"/>
 <result pre="0.5Â Ã— 10âˆ’6 m Chloroquine Diphosphate and 25Â Ã— 10âˆ’6" exact="m" post="Ribavirin). â€œOptimal Combo #2â€� indicates the host cells with"/>
 <result pre="and concurrent treatment with Optimal Combo 2 (5Â Ã— 10âˆ’6" exact="m" post="Amantadine HCl, 5Â Ã— 10âˆ’6 m Azithromycin, 0.5Â Ã—"/>
 <result pre="2 (5Â Ã— 10âˆ’6 m Amantadine HCl, 5Â Ã— 10âˆ’6" exact="m" post="Azithromycin, 0.5Â Ã— 10âˆ’6 m Chloroquine Diphosphate and 0.5Â"/>
 <result pre="Amantadine HCl, 5Â Ã— 10âˆ’6 m Azithromycin, 0.5Â Ã— 10âˆ’6" exact="m" post="Chloroquine Diphosphate and 0.5Â Ã— 10âˆ’6 m Omeprazole Sodium)"/>
 <result pre="0.5Â Ã— 10âˆ’6 m Chloroquine Diphosphate and 0.5Â Ã— 10âˆ’6" exact="m" post="Omeprazole Sodium) The host cell density = 12k, VSV"/>
 <result pre="decisions by patients.[36] These outcomes may also serve as a" exact="foundation" post="for broader clinical deployment of AI to intervene effectively"/>
 <result pre="will be required. 4 Conclusion This work has provided a" exact="foundation" post="toward the rapid identification of dynamically optimized and actionable"/>
 <result pre="strains that may eventually circulate. Given the mechanismâ€� and diseaseâ€�agnostic" exact="foundation" post="of Project IDentif.AI, further studies will evaluate this platform"/>
 <result pre="four concentrations including 0.1, 1, 10, and 100Â Ã— 10âˆ’6" exact="m" post="during the drug optimization process. The concentrations of naproxen"/>
 <result pre="was adopted. 1 equivalent dose refers to 5Â Ã— 10âˆ’6" exact="m" post="for naproxen sodium and ribavirin, and 1Â Ã— 10âˆ’6"/>
 <result pre="m for naproxen sodium and ribavirin, and 1Â Ã— 10âˆ’6" exact="m" post="for the others. Thus, the accumulative equivalent dose of"/>
 <result pre="distance from point k to the projection p on axis" exact="i" post="is D k , i = âˆ‘ s â‰"/>
 <result pre="the projection p on axis i is D k ," exact="i" post="= âˆ‘ s â‰ i x k , s"/>
 <result pre="i is D k , i = âˆ‘ s â‰" exact="i" post="x k , s 2 n âˆ’ 1 Where"/>
 <result pre=", s 2 n âˆ’ 1 Where D k ," exact="i" post="is normalized to [0,1], and mapped with a decreasing"/>
 <result pre="and mapped with a decreasing function: f D k ," exact="i" post="= 1 âˆ’ D k , i q The"/>
 <result pre="D k , i = 1 âˆ’ D k ," exact="i" post="q The single drug STRICT score is then defined"/>
 <result pre="which can be denoted as S c o r e" exact="i" post="= âˆ‘ k = 1 m Y k Â·"/>
 <result pre="c o r e i = âˆ‘ k = 1" exact="m" post="Y k Â· x k , i Â· f"/>
 <result pre="k = 1 m Y k Â· x k ," exact="i" post="Â· f D k , i Using this definition,"/>
 <result pre="Â· x k , i Â· f D k ," exact="i" post="Using this definition, the STRICT score can be easily"/>
 <result pre="to multiâ€�drug interactions, if point k is projected to plane" exact="i" post=", j instead of axis i. The normalized distance"/>
 <result pre="of axis i. The normalized distance is D k ," exact="i" post="= âˆ‘ s â‰ i , j x k"/>
 <result pre="distance is D k , i = âˆ‘ s â‰" exact="i" post=", j x k , s 2 n âˆ’"/>
 <result pre="score can be defined as S c o r e" exact="i" post=", j = âˆ‘ k = 1 m Y"/>
 <result pre="r e i , j = âˆ‘ k = 1" exact="m" post="Y k Â· x k , i Â· x"/>
 <result pre="k = 1 m Y k Â· x k ," exact="i" post="Â· x k , j Â· f D k"/>
 <result pre="Â· x k , j Â· f D k ," exact="i" post=", j Conflict of Interest T.K., A.B., E.K.C., D.H.,"/>
</results>
